| Giant Pharmacy #6446 | |
| 4655 Perkiomen Ave, Reading, Pennsylvania 19606 | |
| (610) 406-9644 |
| Name | Giant Pharmacy #6446 |
|---|---|
| Organization Name | Giant Food Stores Llc |
| Location | 4655 Perkiomen Ave, Reading, Pennsylvania 19606 |
| Type | Pharmacy |
| Phone | (610) 406-9644 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Data presented today from a 310 patient, 52 week, double-blind, controlled clinical trial demonstrates that a micronutrient supplement, Replenish+™ delays the progression of AIDS in HIV-infected patients not receiving antiretroviral treatment (ART).
Sucampo Pharmaceuticals, Inc. announced that phase 3 double blind trial of lubiprostone (marketed as AMITIZA (R) in the U.S.) for chronic idiopathic constipation in Japanese patients has been completed.
› Verified 3 days ago
| NPI Number | 1487686499 |
| Organization Name | THE GIANT COMPANY, LLC |
| Doing Business As | GIANT PHARMACY #6446 |
| Type | Pharmacy |
| Address | 4655 Perkiomen Ave, Reading, PA 19606 |
| Phone Number | 610-406-9644 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Data presented today from a 310 patient, 52 week, double-blind, controlled clinical trial demonstrates that a micronutrient supplement, Replenish+™ delays the progression of AIDS in HIV-infected patients not receiving antiretroviral treatment (ART).
Sucampo Pharmaceuticals, Inc. announced that phase 3 double blind trial of lubiprostone (marketed as AMITIZA (R) in the U.S.) for chronic idiopathic constipation in Japanese patients has been completed.
› Verified 3 days ago
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
In a recent study, published in The Oncologist, just under 10% of patients diagnosed with terminal cancer did not know their prognosis and had no interest in finding out.
Data presented today from a 310 patient, 52 week, double-blind, controlled clinical trial demonstrates that a micronutrient supplement, Replenish+™ delays the progression of AIDS in HIV-infected patients not receiving antiretroviral treatment (ART).
Sucampo Pharmaceuticals, Inc. announced that phase 3 double blind trial of lubiprostone (marketed as AMITIZA (R) in the U.S.) for chronic idiopathic constipation in Japanese patients has been completed.
› Verified 3 days ago
David Foster Type: Eyewear Supplier (Equipment, not the service) Location: 2504 Perkiomen Ave, Reading, Pennsylvania 19606 Phone: (610) 779-9636 | |
Giant Pharm #6050 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2641 Shillington Rd, Reading, Pennsylvania 19608 Phone: (610) 678-3335 | |
Giant Pharmacy #6446 Type: Pharmacy Location: 4655 Perkiomen Ave, Reading, Pennsylvania 19606 Phone: (610) 406-9644 | |
Prosthetic - Orthotic Services Type: Prosthetic/Orthotic Supplier Location: 114 N 9th St, Reading, Pennsylvania 19601 Phone: (610) 373-6860 | |
Inhome Oxygen And Medical Supplies, Type: Durable Medical Equipment & Medical Supplies Supplier Location: 103 Lancaster Ave, Reading, Pennsylvania 19611 Phone: (610) 929-2004 |